After a breast cancer diagnosis, one of the hardest questions is whether it will come back.
@SimBioSys is helping doctors and patients better understand that risk. Powered by NVIDIA technology, its FDA-cleared TumorSight Risk analyzes an existing breast MRI alongside pathology
